← back to search

Zvi Ram

Tel Aviv University · IL
Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Meningioma and schwannoma management, and Pituitary Gland Disorders and Treatments.
h-index
66
citations
22,777
works
365
NIH funding
primary concept
email

Recent publications

A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification
Nature Genetics 2026cited by 3position: middledoi
Updated clinical practice guidelines for the management of adult diffuse gliomas
Cancer Letters 2025cited by 3position: middledoi
Identifying proximity to white matter language tracts with gradient-based intraoperative electrical mapping
Journal of neurosurgery 2025cited by 0position: middledoi
The default network is causally linked to creative thinking
Molecular Psychiatry 2022cited by 61position: lastdoi
Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases
Journal of Neuro-Oncology 2022cited by 37position: middledoi
Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)
Discover Oncology 2022cited by 17position: lastdoi
Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 10position: middledoi
Clinical practice guidelines for the management of adult diffuse gliomas
Cancer Letters 2020cited by 467position: middledoi
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
Acta Neuropathologica 2019cited by 90position: middledoi
The Impact of Colloid Cyst Treatment on Neurocognition
World Neurosurgery 2019cited by 13position: contributordoi
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma
JAMA Oncology 2018cited by 185position: middledoi
Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins
Theranostics 2018cited by 69position: middledoi
Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma
The FASEB Journal 2018cited by 15position: middledoi
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
JAMA 2017cited by 2,549position: lastdoi
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) 2017cited by 641position: lastdoi
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a <i>post hoc</i> analysis of the EF-14 trial
CNS Oncology 2017cited by 69position: middledoi
Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature
Acta Neuropathologica 2017cited by 31position: middledoi
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 2015cited by 1,216position: lastdoi
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
The Lancet Oncology 2014cited by 750position: middledoi
Response assessment of NovoTTF‐100A versus best physician's choice chemotherapy in recurrent glioblastoma
Cancer Medicine 2014cited by 53position: middledoi
Conflicting pathology reports: a diagnostic dilemma
Journal of neurosurgery 2014cited by 3position: middledoi
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
The Lancet Oncology 2013cited by 238position: lastdoi
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
European Journal of Cancer 2012cited by 840position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 4 papers (2018–2022)Moran Artzi · Tel Aviv University2 papers (2022–2025)John L. Villano · University of Kentucky2 papers (2014–2018)Andrew A. Kanner · Tel Aviv University2 papers (2014–2018) · 2 papers (2014–2018)Ben Shofty · University of Utah2 papers (2022–2022) · 2 papers (2018–2018) · 2 papers (2018–2018)Roger Stupp · Northwestern University2 papers (2014–2018) · 2 papers (2018–2018)Jérôme Honnorat · Université Claude Bernard Lyon 12 papers (2018–2022) · 2 papers (2018–2018) · 2 papers (2022–2025) · 2 papers (2018–2018) · 2 papers (2018–2018) · 1 papers (2014–2014)Emmanuelle Merquiol · Hebrew University of Jerusalem1 papers (2018–2018)Erez Nossek · New York University1 papers (2014–2014)Olivier Chinot · Peuplements végétaux et bioagresseurs en milieu tropical1 papers (2014–2014) · 1 papers (2018–2018)